Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03EGA
|
|||
| Former ID |
DIB020988
|
|||
| Drug Name |
SRT1720
|
|||
| Synonyms |
925434-55-5; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide; SRT 1720; SRT-1720; SRT1720; CHEMBL257991; N-[2-[3-(1-PIPERAZINYLMETHYL)IMIDAZO[2,1-B]THIAZOL-6-YL]PHENYL]-2-QUINOXALINECARBOXAMIDE; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide; Tafluprost enone; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide; IASPBORHOMBZMY-UHFFFAOYSA-N
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C25H24ClN7OS
|
|||
| Canonical SMILES |
C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl
|
|||
| InChI |
1S/C25H23N7OS.ClH/c33-24(22-13-27-20-7-3-4-8-21(20)28-22)29-19-6-2-1-5-18(19)23-15-32-17(16-34-25(32)30-23)14-31-11-9-26-10-12-31;/h1-8,13,15-16,26H,9-12,14H2,(H,29,33);1H
|
|||
| InChIKey |
DTGRRMPPXCRRIM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1001645-58-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
48412536, 56072363, 99460882, 103563410, 104097840, 124893771, 124893772, 141483860, 152258247, 160647083, 160825152, 162158018, 162202784, 163092466, 163384436, 163840337, 165236819, 170559104, 172088859, 173019921, 186014828, 188899577, 198992051, 202562382, 204366497, 223366036, 223592782, 227223342, 244838855, 252216338, 252303031, 252451835, 252490903
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | NAD-dependent deacetylase sirtuin-1 (SIRT1) | Target Info | Activator | [1] |
| KEGG Pathway | FoxO signaling pathway | |||
| AMPK signaling pathway | ||||
| Glucagon signaling pathway | ||||
| Amphetamine addiction | ||||
| MicroRNAs in cancer | ||||
| Panther Pathway | p53 pathway | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| Signaling events mediated by HDAC Class III | ||||
| E2F transcription factor network | ||||
| HIF-2-alpha transcription factor network | ||||
| Signaling events mediated by HDAC Class I | ||||
| FoxO family signaling | ||||
| Regulation of Androgen receptor activity | ||||
| Regulation of retinoblastoma protein | ||||
| Reactome | RORA activates gene expression | |||
| Regulation of HSF1-mediated heat shock response | ||||
| Circadian Clock | ||||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Integrated Breast Cancer Pathway | ||||
| SREBP signalling | ||||
| Androgen receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.